<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129063</url>
  </required_header>
  <id_info>
    <org_study_id>PKM11086</org_study_id>
    <secondary_id>2008-008450-22</secondary_id>
    <nct_id>NCT01129063</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects</brief_title>
  <official_title>An Open-label, Two-treatment Crossover Pharmacokinetic Study of Clopidogrel Hydrogen Sulfate in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to:

        -  Assess the within-subject variability of the pharmacokinetic profiles of the clopidogrel
           and its active metabolite after a replicated single administration of 75 mg of
           clopidogrel in healthy male and female subjects

        -  Assess the pharmacokinetic profiles of the clopidogrel and its active metabolite after
           single administration of 75 or 300 mg of clopidogrel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per subject is 4 - 6 weeks broken down as follows:

        -  Screening: 2 to 21 days before the first dosing

        -  Period 1, 2 and 3: 4 days including 1 treatment day each

        -  Washout between periods: at least 7 days between 2 administrations

        -  End of study: 7 to 10 days after the last dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clopidogrel pharmacokinetic parameters (Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUC))</measure>
    <time_frame>Up to 48 hours postdose for each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clopidogrel active metabolite pharmacokinetic parameters (Cmax, AUClast and AUC)</measure>
    <time_frame>Up to 48 hours postdose for each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other clopidogrel pharmacokinetic parameters (first time to reach Cmax (tmax), terminal half-life (t1/2z))</measure>
    <time_frame>Up to 48 hours postdose for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clopidogrel active metabolite pharmacokinetic parameters (tmax, t1/2z)</measure>
    <time_frame>Up to 48 hours postdose for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence clopidogrel 75 / 75 / 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: clopidogrel 75 mg single dose
Period 2: clopidogrel 75 mg single dose
Period 3: clopidogrel 300 mg single dose
Each intake is at around 8:00 AM under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Pharmaceutical form : tablet
Route of administration: oral</description>
    <arm_group_label>Sequence clopidogrel 75 / 75 / 300 mg</arm_group_label>
    <other_name>SR25990</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects:

          -  as determined by medical history and complete physical examination including vital
             signs and clinical laboratory tests

          -  with a body weight between 50kg and 95 kg if male, between 40.0 kg and 85.0 kg if
             female and a Body Mass Index (BMI) between 18 and 28 kg/m2

        Exclusion Criteria:

          -  Evidence of inherited disorder of coagulation/hemostasis functions

          -  Smoking more than 5 cigarettes or equivalent per day

          -  Abnormal hemostasis screen

          -  Any contraindication to clopidogrel

          -  Unability to abstain from intake of any drug affecting haemostasis throughout the
             whole study duration.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>International Clinical Development Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

